| DB ID | MyCo_2543 |
| Title | Lower beta-1,3-D-glucan testing cut-offs increase sensitivity for non-albicans Candida species bloodstream infections |
| Year | 2022 |
| PMID | 35020235 |
| Fungal Diseases involved | Candidemia |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | None |
| Cohort No. | 82 Patients |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Candidemia is a life-threatening condition with high mortality of up to 60%. Particularly patients with malignancies, immunosuppression, abdominal surgery and need for intensive care treatment are at risk. Due to the ongoing development of treatment options in modern medicine, the number of patients at risk is increasing. Therefore, an increasing burden of fungal bloodstream infections was observed over the recent years in many parts of the world. Despite new antifungal drugs and improved treatment algorithms, management of candidemia is challenging and mortality remains high. Therefore, early diagnosis is essential, as prompt anti-infective therapy promotes a favourable outcome. |
| Technique | Assay |
| Analysis Method | ELISA Based |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |